Sildenafil reduces Raynaud's frequency in patients with systemic sclerosis
Wednesday, March 9, 2011 - 13:40
in Health & Medicine
Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud's phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor or moderate side effects. Full findings are available in the March issue of Arthritis and Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR)...